IgA is the most prevalent antibody type on mucosal surfaces and the second most prevalent antibody in circulation, yet its role in immune defense is not fully understood. Here we show that IgA is carried inside cells during virus infection, where it activates intracellular virus neutralization and innate immune signaling. Cytosolic IgA-virion complexes colocalize with the high-affinity antibody receptor tripartite motif-containing protein 21 (TRIM21) and are positive for lysine-48 ubiquitin chains. IgA neutralizes adenovirus infection in a TRIM21-and proteasome-dependent manner in both human and mouse cells. Translocated IgA also potently activates NF-κB signaling pathways in cells expressing TRIM21, whereas viral infection in the absence of antibody or TRIM21 is undetected. TRIM21 recognizes an epitope in IgG Fc that is not conserved in IgA; however, fluorescence anisotropy experiments demonstrate that direct binding to IgA is maintained. We use molecular modeling to show that TRIM21 forms a nonspecific hydrophobic seal around a β-loop structure that is present in IgG, IgM, and IgA, explaining how TRIM21 achieves such remarkable broad antibody specificity. The findings demonstrate that the antiviral protection afforded by IgA extends to the intracellular cytosolic environment.
IgA is the most prevalent antibody type on mucosal surfaces and the second most prevalent antibody in circulation, yet its role in immune defense is not fully understood. Here we show that IgA is carried inside cells during virus infection, where it activates intracellular virus neutralization and innate immune signaling. Cytosolic IgA-virion complexes colocalize with the high-affinity antibody receptor tripartite motif-containing protein 21 (TRIM21) and are positive for lysine-48 ubiquitin chains. IgA neutralizes adenovirus infection in a TRIM21-and proteasome-dependent manner in both human and mouse cells. Translocated IgA also potently activates NF-κB signaling pathways in cells expressing TRIM21, whereas viral infection in the absence of antibody or TRIM21 is undetected. TRIM21 recognizes an epitope in IgG Fc that is not conserved in IgA; however, fluorescence anisotropy experiments demonstrate that direct binding to IgA is maintained. We use molecular modeling to show that TRIM21 forms a nonspecific hydrophobic seal around a β-loop structure that is present in IgG, IgM, and IgA, explaining how TRIM21 achieves such remarkable broad antibody specificity. The findings demonstrate that the antiviral protection afforded by IgA extends to the intracellular cytosolic environment. M ore IgA is produced per day in the human body than all of the other antibody isotypes combined (1) . Humans express two IgA isotypes, IgA1 and IgA2, and each isotype is expressed in several oligomeric states including, monomeric (mIgA), dimeric (dIgA), and secretory (S-IgA) (1) . S-IgA plays a key immune role at mucosal surfaces as the critical first line of defense against inhaled or ingested pathogens, as well as confining commensal bacteria to the intestinal lumen; however, serum IgA also plays a significant but less well understood immune role (2) . Circulating serum IgA, which is predominantly mIgA1, is found at concentrations of 2-3 mg/mL, making it the second most prevalent antibody class in plasma after IgG (3) . During infection, pathogens are bound by mIgA, which is able to interact with and aggregate Fcα receptor I (FcαRI) molecules. Receptor activation promotes phagocytosis, antigen presentation, antibody-dependent cellular cytotoxicity, cytokine, and superoxide release (4) . However, FcαRI, like most Fc receptors, is exclusively expressed on professional myeloid cells (5, 6) . Viral neutralization is mediated by antibodies whose in vitro binding to a virus can cause a reduction in infectious titer independently of effector mechanisms such as Fc-mediated phagocytosis or complement fixation (7) . Recently, we discovered a neutralization pathway mediated by the cytosolic antibody receptor, tripartite motif-containing protein 21 (TRIM21), which is expressed in most tissue types and not just professional cells (8, 9) . TRIM21 binds to IgG molecules that have been carried inside cells by infecting virus particles (8) . TRIM21 binds IgG Fc via its C-terminal PRYSPRY domain at subnanomolar affinity, making it one of the highest-affinity IgG Fc receptors in the human body (8, 10) . After binding a virion-associated antibody, TRIM21 targets the cytosolic antibody-virus complex for proteasomal degradation in a process called antibody-dependent intracellular neutralization (ADIN) (8, 11) . In addition to mediating ADIN, TRIM21 stimulates the NF-κB, activator protein 1 (AP-1), and interferon regulatory factors IRF3/IRF5/IRF7 immune signaling pathways and induces an antiviral state (12) . Interestingly, TRIM21 can also perform these immune functions by binding to cytosolic virion-associated IgM molecules (8, 12) . Use of both IgG and IgM is unusual as most antibody receptors are strongly isotype specific.
In this study, we investigated whether TRIM21 can use IgA molecules to stimulate viral neutralization or innate immune signaling. We find that TRIM21 can bind directly to IgA and that it recognizes virion-associated IgA inside infected cells. By recruiting TRIM21, IgA mediates virus neutralization in the cytosol and potently activates NF-κB. These data demonstrate that circulatory IgA has a broader role to play in combatting viral infection than previously recognized and identifies TRIM21 as a uniquely broad isotype receptor.
Results
IgA Enters Cells During Viral Infection and Is Detected by TRIM21. To investigate whether IgA antibodies enter cells during viral infection, replication-deficient human adenovirus type 5-GFP (AdV) was incubated with pooled human serum IgA (hIgA) and added to HeLa cells. Thirty minutes after infection, cells were fixed and incubated with labeled anti-human IgA and anti-adenovirus IgG. hIgA was detected inside HeLa cells and colocalized to intracellular AdV (Fig. 1A) . To determine whether TRIM21 can bind directly to IgA, an in vitro fluorescence anisotropy experiment was performed. IgA was titrated into Alexa 488-labeled TRIM21 PRYSPRY, and the change in anisotropy was measured. Fitting the resulting data revealed that IgA binds TRIM21 with an affinity (K D ) of 50 ± 24 μM (Fig. 1B) . We also measured binding of purified IgA1 and IgA2 and obtained affinities of 55 μM ± 23 and 53 ± 39 μM, respectively (Fig. S1 ). The TRIM21 PRYSPRY domain has previously been shown to bind IgG and IgM with a K D of ∼150 nM and ∼17 μM, respectively (8, 10, 13 ). An affinity of 50 μM is relatively weak; however, this represents monomeric binding, and it is
Significance
In recent years, the important immune protective role of IgA, the most plentiful antibody type, has become increasingly clear. In this study, we show that IgA is carried inside cells during infection by a nonenveloped virus, adenovirus, which commonly causes respiratory disease. Once inside the cell, IgA is recognized by the newly identified cytosolic antibody receptor, tripartite motifcontaining protein 21 (TRIM21), leading to destruction of virus by the proteasome and immune activation. We show that TRIM21 interacts directly with IgA to initiate these responses and explain how binding is accomplished. Our work identifies TRIM21 as the only antibody receptor to bind the three most prevalent circulatory antibodies, IgG, IgM, and IgA, and enlarges the role of IgA in immune protection.
likely to be stronger in the context of full-length dimeric TRIM21. Given that full-length dimeric TRIM21 binds IgG with a K D of 0.4 nM (8), an increase over monomeric affinity of ∼375-fold, the physiological binding affinity of TRIM21 for IgA, is likely to be submicromolar.
To test whether TRIM21:IgA binding occurs during viral infection, TRIM21 localization was determined following infection of cells with AdV-hIgA complexes. Staining for hIgA and TRIM21 revealed that TRIM21 colocalizes to intracellular hIgA-positive virions (Fig. 1C) . It has previously been shown that intracellular TRIM21-IgG-AdV complexes are also positive for ubiquitin (8) . Costaining for ubiquitin showed that K48-ubiquitin chains are associated with TRIM21-hIgA-AdV complexes (Fig. 1C) . Together, this suggested that TRIM21 binds intracellular IgAcoated AdV and that this may lead to ubiquitination of the viral complex and downstream immune responses.
IgA Mediates Intracellular Neutralization via TRIM21. Next, we investigated whether TRIM21 can mediate intracellular neutralization upon recognition of cytosolic IgA-bound virus. HeLa cells depleted of TRIM21, stimulated with IFN-α to increase TRIM21 expression, or both were infected with AdV preincubated with either hIgA or a buffer control. In cells treated with control siRNAs, a 20-fold neutralization of AdV infection by hIgA was observed. However, in cells depleted of TRIM21, neutralization was reduced, while in cells treated with IFN-α, neutralization was increased ( Fig. 2A) . As IFN-α up-regulates the expression of many genes, we confirmed that the changes in neutralization potency seen here could be assigned to altered TRIM21 levels by repeating our assay on cells stimulated with IFN-α and depleted of TRIM21. IFN-α treatment restored the viral neutralization phenotype in TRIM21-depleted cells, suggesting that IFN-α can alter viral infectivity by increasing cellular TRIM21 levels. The influence of each treatment on cellular TRIM21 levels was confirmed by Western blotting (Fig. 2B) .
The stoichiometric requirement for neutralization influences the profile of neutralization curves (14) . First-order dynamics result in a straight line when remaining infectivity is plotted on a logarithmic scale. In contrast, when a threshold number of antibodies is required (multihit model) for neutralization, a lag can be detected. It has previously been demonstrated that TRIM21 exhibits characteristic first-order neutralization but that with polyclonal sera, when TRIM21 is depleted, a shift to multihit neutralization is observed (11) . To investigate the dynamics of hIgA-mediated intracellular neutralization, we preincubated AdV with a titration of hIgA concentrations before infection. We observed a rapid decrease in infection with increasing hIgA concentrations (Fig. 2C ). Moreover, changing the level of cellular TRIM21 altered the gradient and shape of the neutralization curves. In cells with high TRIM21 levels, there was an initial linear relationship between virus neutralization and hIgA concentration (Fig. 2C) . Conversely, in cells depleted of TRIM21, the neutralization curve was shallower with a perceptible lag. The appearance of a lag indicates that a critical number of antibodies is necessary before neutralization is observed. The requirement for a critical number of antibodies is indicative of a TRIM21-independent neutralization mechanism, such as entry blocking, where antibodies must occlude all available host receptor-binding sites on the virus to be effective. Thus, serum IgA, in a similar manner to polyclonal IgG (11, 14) , possesses antibodies that neutralize through multiple mechanisms, but a significant component is dependent on TRIM21.
S-IgA is an oligomeric IgA species linked by the J chain and secretory component (SC) and found both on mucosal surfaces and in mammalian breast milk. We tested whether TRIM21 can use S-IgA to inhibit AdV infection. Of five commercially available human S-IgA preparations derived from colostrum, three did not contain AdV-neutralizing antibodies, whereas two gave a dosedependent inhibition of infection ( Fig. 2D and Fig. S2 ). Of these, one neutralized infection independently of TRIM21, whereas in the other, depletion of TRIM21 partially rescued infection. The ability of TRIM21 to use S-IgA was surprising given that the SC binding site overlaps TRIM21 (15) , although the SC is not thought to engage both heavy chains in each IgA monomer (16) . In fluorescence titration experiments, an increase in anisotropy was observed on addition of S-IgA to TRIM21 PRYSPRY, but a sufficiently high concentration of antibody could not be reached to determine affinity (Fig. 2E) . Nevertheless, comparison with the serum IgA data suggests that the presence of the SC is inhibitory to TRIM21 binding of IgA. The association of SC with IgA is dependent on disulphide bridges: both because of a direct covalent bond with C α 2 and indirectly because the J-chain is required and it also forms disulphide bridges, with a cysteine at the end of C α 3 (16) . Given that the cytosol of the cell is reducing, unlike endocytic compartments or the extracellular environment, we hypothesized that perhaps the J chain and SC detach from S-IgA when it is brought into the cytosol by virus. When S-IgA titrations were repeated in the presence of 1 mM DTT, we observed a dramatic increase in binding to TRIM21 PRYSPRY and measured an affinity approximating that for serum IgA (31 ± 16 μM; Fig. 2F ).
The efficiency with which TRIM21 mediates neutralization using IgA is difficult to determine from experiments with pooled serum antibody, due to the heterogeneity in specificity and titer. To generate an IgA species of known specificity, which would not cause blockage to viral entry, we class-switched a mouse monoclonal anti-hexon IgG1, 9C12, which we have previously shown to neutralize almost exclusively through TRIM21 (11) . To achieve this, the V H domain, C H 1 domain, and hinge region of 9C12 were cloned onto the C α 2 and C α 3 domains of human IgA1. The engineered IgA heavy chain was expressed with the 9C12 kappa light chain using a bicistronic expression system in human cells. The efficiency of neutralization mediated by this engineered antihexon IgA (9A; Fig. S3 ) was tested in mouse embryonic fibroblast (MEF) cells derived from WT (TRIM21
) and TRIM21 KO (K21; TRIM21 −/− ) mice (9) . In WT cells, 9A induced potent neutralization of AdV, but in K21 cells, neutralization was significantly reduced (Fig. 3A) . For comparison, a similar experiment was performed with the 9C12 IgG, which gave potent IgG and TRIM21-dependent neutralization (Fig. 3A) . Together these experiments show that TRIM21 can use IgA for intracellular neutralization although less efficiently than with IgG.
Intracellular IgA Neutralization Requires the AAA ATPase ValosinContaining Protein (VCP) and the Proteasome. Next, we investigated whether TRIM21-mediated IgA neutralization occurs via the same intracellular mechanism as with IgG. On recognition of an IgG-bound cytoplasmic AdV, TRIM21 targets the virus for proteasomal degradation (8) . To test whether hIgA-mediated neutralization occurs through a similar mechanism, HeLa cells were treated with the proteasome inhibitor, epoxomicin, or with DMSO as a control, before infection with AdV preincubated with hIgA or buffer (Fig. 3B) . Neutralization was abrogated when the proteasome was inhibited, suggesting that hIgA was mediating intracellular neutralization via a similar mechanism to the previously characterized isotypes IgG and IgM (8) . A requirement for the proteasome during IgA-mediated intracellular neutralization was further confirmed by treatment of WT and K21 MEF cells with epoxomicin, the proteasome inhibitor MG132, or DMSO as a solvent control before infection with AdV preincubated with either class-switched monoclonal 9A or buffer. Proteasome inhibition reversed the TRIM21-dependent neutralization (Fig. 3C) . In addition to the proteasome, ADIN has also been shown to be dependent on the AAA ATPase valosincontaining protein (VCP) but independent of autophagy (8, 17) . Treatment of WT and K21 cells with either the VCP inhibitor N2,N4-dibenzylquinazoline-2,4-diamine (DBeQ) or the autophagy inhibitor Gö6976 (18) before infection revealed that only VCP inhibition efficiently abrogated neutralization (Fig. 3C) . Thus, although IgA mediates a less potent intracellular neutralization than IgG and IgM, it is harnessing the same TRIM21-dependent downstream degradation pathway.
High levels of neutralizing antibody frequently result in a proportion of viruses that remain nonneutralizable, termed the persistent fraction. We have previously shown that the persistent fraction is influenced by the cellular abundance of TRIM21 (11) . Given that TRIM21 has a reduced affinity to IgA, we hypothesized that changing TRIM21 abundance should have a significant effect on the level of persistent fraction observed during 9A neutralization. To investigate this, WT and K21 cells were treated with epoxomicin or DMSO before infection with AdV preincubated with increasing concentrations of 9A (Fig. 3D) . In both cell types, independent of inhibitor treatment, we saw that the addition of 9A above 10 μg/mL concentrations gave no further increase in the level of neutralization, suggesting that the persistent fraction had been reached. In DMSO-treated WT cells, the remaining infectivity at this concentration of 9A was 14%. This persistent fraction was largely dependent on the TRIM21/proteasome pathway as inhibition of the proteasome in WT-treated cells increased the persistent fraction to a level similar to that seen in the DMSO treated K21 cells. Interestingly, inhibition of the proteasome in K21 cells slightly increased the persistent fraction, suggesting that there may be another intracellular IgA receptor.
TRIM21 Uses IgA to Inhibit a Spreading Adenovirus Infection. To determine the importance of IgA neutralization during replication of a fully competent human adenovirus, HeLa cells either stably transduced with an empty vector control (HeLa EV) or stably expressing an shRNA to deplete cellular TRIM21 levels (HeLa shT21) were infected with a WT human adenovirus 5 (WT AdV) preincubated with hIgA. The neutralizing titer was quantified by limited serial dilution, measuring percentage cell survival by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay 1 wk after infection (Fig. 4A) . No cell viability could be detected at low concentrations of hIgA; however, the percentage of viable cells increased with increasing antibody concentration until, at concentrations close to serum levels of hIgA, the antibody was seen to be fully protective in both cell types. This titration suggests that IgA neutralization can have a significant role during WT AdV infection. In HeLa cells depleted of TRIM21, higher concentrations of hIgA were required to mediate a similar level of protection, suggesting that TRIM21-mediated ADIN contributes to this protective effect.
The degree to which TRIM21 is important in neutralization is predicted to be a function of antibody specificity. To determine how efficient ADIN can be in blocking a spreading WT AdV infection in the presence of a specific anti-adenovirus antibody, we repeated our experiments using WT AdV preincubated with a titration of engineered monoclonal IgA, 9A (Fig. 4B) . As before, cell viability increased with increasing antibody concentration; however, in HeLa cells depleted of TRIM21, a 16-fold higher concentration of 9A was required to mediate a similar level of neutralization. Even at the highest 9A concentration tested, 80 μg/mL, cell viability was only 20% in TRIM21-depleted cells, whereas 9A was fully protective at the same concentration in cells expressing TRIM21. This comparison suggests that IgA can mediate efficient TRIM21-dependent intracellular neutralization to prevent the spreading infection of a WT fully replication competent adenovirus. Next, we used our spreading infection assay to determine the efficiency with which TRIM21 can use IgG compared with IgA to prevent WT AdV replication. WT AdV was preincubated with increasing concentrations of 9C12, the parent IgG antibody of 9A (Fig. 4C) . In cells depleted of TRIM21, little virus neutralization was detected except at the highest concentrations of 9C12. This minimal protection was similar to the protection observed with 9A at the same concentrations. However, in cells expressing TRIM21, 9C12 was effective even at very low antibody concentrations, and complete protection was achieved at concentrations fourfold lower than those required for 9A. This result demonstrates that, although both IgA and IgG can activate TRIM21-dependent ADIN, IgG is the more potent isotype.
Intracellular IgA Is a DAMP That Activates NF-κB. TRIM21 recognition of cytosolic IgG and IgM stimulates innate immune signaling and promotes NF-κB activation (12) . To investigate whether cytosolic IgA also activates TRIM21 signaling, an NF-κB reporter construct was transiently transfected into HeLa EV cells and HeLa shT21 cells. TRIM21 is not required for constitutive NF-κB signaling, and the expression of the reporter constructs in both cell lines was confirmed by stimulation with TNFα as described previously (12) . The NF-κB reporter cells were challenged with AdV, hIgA, or AdV + hIgA, and their ability to stimulate NF-κB was compared. Neither AdV nor hIgA alone stimulated NF-κB signaling in either cell line. However, in HeLa cells infected with AdV + hIgA, there was a 60-fold induction of NF-κB signaling compared with a 2-fold change in HeLa shT21 cells (Fig. 5A) . The same experiment was performed in parallel with human serum IgG (hIgG). Neither AdV nor hIgG alone stimulated NF-κB signaling in either cell line. However, in HeLa cells infected with AdV + hIgG, there was a 50-fold induction of NF-κB signaling compared with a 2-fold change in HeLa shT21 cells (Fig. 5B) . This finding suggests that, like IgG and IgM, cytosolic IgA antibodies are recognized as a danger-associated molecular pattern (DAMP) by TRIM21 and that their recognition activates NF-κB signaling (12) . Moreover, without TRIM21 sensing of bound hIgA, virus infection was not sensed by cells in our experiments. To determine whether the activation of NF-κB following TRIM21 recognition of cytosolic IgA is sufficient to induce proinflammatory cytokine secretion, we tested cytokine levels 24 h after infection. We observed robust secretion of IFN-β, TNF, IL-6, and CXCL10 only in cells infected with AdV + hIgA (Fig. 5C) . Furthermore, depletion of TRIM21 significantly inhibited secretion suggesting that the context-dependent recognition of IgA by TRIM21 plays an important role in cellular detection of AdV infection.
TRIM21 Uses a Degenerate Binding Mechanism to Bind IgA, IgM, and
IgG. There are no previously described examples of an Fc receptor that can functionally interact with IgG, IgM, and IgA. Most Fc receptors are highly isotype and subtype specific, in part because of sequence variation between these antibodies. We investigated how TRIM21 detects all three antibody isotypes. Sequence comparison reveals that the hot spot residues in IgG Fc that are targeted by TRIM21 and essential for its antiviral role are not conserved in IgA (Fig. S4A) . We have previously shown that mutation of any one of these IgG hot-spot residues (H433, N434, and H435) to alanine greatly diminishes TRIM21 mediated neutralization (11) . In addition, the single point mutation N434D is sufficient to severely impair TRIM21-dependent NF-κB signaling (12) . However, in IgA, the equivalent residues to the IgG HNH motif are P440, L441, and A442. This sequence difference raises the question of how TRIM21 accommodates three different hotspot residues in IgA, if it is so sensitive to their mutation in IgG.
We attempted to characterize the binding interface between IgA and TRIM21 by determining an X-ray structure of IgA Fc in complex with TRIM21 PRYSPRY but were unable to attain diffraction quality crystals. However, as there is a previously solved structure of IgA Fc in complex with human FcαRI (CD89) (19), we used this together with our structure of IgG Fc in complex with TRIM21 PRYSPRY (10) to obtain a model. The complexes were aligned using a secondary structure matching algorithm in Coot (20) to overlay the Fc domains. The heavy chains of IgG and IgA superposed closely (root mean square deviation of 3.3 Å for Cα atoms) due to the high conservation of their overall architecture (Fig. S4B ). This close superposition validates the use of a structural homology model to predict TRIM21:IgA binding.
In the IgG Fc:TRIM21 PRYSPRY structure, the Fc HNH motif is located in a loop between the final two β-strands of the C H 3 domain. This loop forms a finger-like projection that is enclosed within the concave binding pocket of TRIM21 PRYSPRY and surrounded by a ring of hydrophobic residues (Y328, L370, L371, W381, W383, and F450). This projecting loop is conserved in IgA, with IgG loop residues H433, N434, H435, and Y436 replaced by P440, L441, A442, and F443 (Fig. 6 ). These alternate IgA residues have reduced hydrogen bond potential but increased hydrophobicity. The ring of hydrophobic residues in the binding site of TRIM21 are positioned to form a hydrophobic seal around the PLAF sequence, and it is likely that this is what drives binding to IgA. In IgG, residues H433 and N434 form hydrogen bonds with TRIM21 residue D355. IgA has a proline in place of H433, which cannot form a hydrogen bond, but can make stacking interactions with TRIM21 residues W381 and W383 (Fig. 6) . Although proline-tryptophan interactions are not aromatic-aromatic pairings, they generate considerable binding energy, ∼7 kcal/mol, approximately twice that of a typical hydrogen bond (21) . IgA L441, equivalent to IgG N434, may also contribute to binding through hydrophobic interaction with TRIM21 residues L370, L371, and Y328. IgA A442 is unlikely to mediate any interactions with TRIM21, but F443 is positioned to form similar packing interactions as Y436 in IgG (Fig. 6) . Indeed, position 436 varies between IgGs of different species; for instance, it is often histidine in mouse IgG, and these changes can be accommodated by TRIM21 (13) . Thus, the TRIM21:IgA Fc interface is likely primarily held together by hydrophobic forces, explaining how sequence divergence is accommodated. Moreover, the replacement of some specific hydrogen bonds mediated by the IgG binding loop with weaker nonpolar interactions formed by structurally equivalent residues in IgA may explain why IgA is bound more weakly by TRIM21. In turn, the weaker binding affinity may be the reason why IgA-mediated ADIN is less efficient than IgG-mediated ADIN. Interestingly, the Fcα PLAF loop is critical in mediating interactions with multiple proteins including the human Fc receptors FcαRI, Fcα/μR, the polymeric Ig receptor (pIgR), the pathogenproduced antigens SSL7 from Staphylococcus aureus, M proteins, Sir22, and ARP4 from group A streptococci, β-protein from group B streptococci, and the type 2 IgA1 protease produced by Neisseria meningitidis (15, 19, (22) (23) (24) (25) (26) (27) . Unlike TRIM21, however, these IgA receptors are more isotype specific (although Fcα/μR interacts with both IgA and IgM). For example, mutation of any one of the PLAF residues results in the elimination of FcαRI-mediated rosetting in neutrophils (22, 23) . To explain why FcαRI lacks the broad binding capability of TRIM21, we used the superposed complexes described above and generated a model of IgG Fc:FcαRI. In this model, it is clear that, unlike with TRIM21, swapping IgA for IgG results in the loss of specific interactions, the absence of compensating interactions, and the generation of binding site clashes. In particular, the hydrogen bond between IgA P440 and FcαRI H85 (Fig. S4C ) cannot form with IgG; instead, H85 would clash with H435 in the IgG HNH motif. This comparison between FcαRI and TRIM21 demonstrates that the ability of the latter to use a broad range of antibody types is a consequence of the specific binding mechanism it has evolved.
Discussion
Our data suggest that both serum and secretory IgA antibodies can trigger cytosolic immune defense mechanisms when carried into cells by an invading virus. Intracellular virion-associated IgA molecules are recognized by the cytosolic antibody receptor TRIM21, stimulating both ADIN and innate immune signaling. Serum IgA antibodies of both subclasses (IgA1 and IgA2) bind TRIM21 with similar affinity, consistent with the fact that they share the same TRIM21 epitope sequence (PLAF motif) and previous studies showing that they interact equally with pIgR (15) . Secretory IgA shows reduced binding to TRIM21, presumably as a consequence of the secretory chain; however, under reducing conditions, a similar binding affinity to TRIM21 as serum IgA is observed. Together with previous data, this reveals TRIM21 as a unique broadly specific Ig receptor. Molecular modeling has enabled us to predict how TRIM21 binds to IgA. TRIM21 forms a hydrophobic seal around a β-loop structure that is conserved in IgA, using a ring of conserved hydrophobic residues surrounding a concave binding site. The nature of these nonspecific interactions means that sequence variation within the loop can be accommodated.
Our data also suggest that the antiviral protection provided by IgA is mediated by a mixture of ADIN and other neutralization mechanisms. IgA-stimulated ADIN makes a significant contribution, and at subphysiological hIgA concentrations, we observed an ∼20-fold reduction in infectivity, mediated by TRIM21. Importantly, we also found that hIgA acts as a potent cytoplasmic DAMP. Cytosolic IgA-coated viruses are sufficient to activate NF-κB and induce proinflammatory cytokine secretion, and this may be important in detecting virions that otherwise escape invariant pattern recognition receptors such as Toll-like receptors. The interaction of mIgA and dIgA with FcαRI has been shown to stimulate NF-κB signaling; however, FcαRI is only expressed by myeloid cells (7, 28) . By contrast, TRIM21 is universally expressed and thus may allow IgA to stimulate innate immunity without relying on immune surveillance.
It is important to note that in our experiments, the virus:IgA complex is being recognized by the receptor for the virus that is expressed on permissive cell types. By standard definitions, the antibody is not preventing internalization and is therefore nonneutralizing. It is the interaction with TRIM21 that takes place after the virus:IgA complex has entered the cytosol that allows the antibody to become neutralizing. This system is unrelated to previously described reports of IgA-mediated intracellular neutralization in which IgA or the virus-IgA complex is taken up by FcαR. For instance, it has been shown that endosomal dIgA can mediate a form of intracellular viral neutralization during pIgR-mediated transcytosis through epithelial cells infected with Sendai virus, rotavirus, or HIV (29) (30) (31) . For example, in the case of HIV, transcytosing IgA meets endocytosed HIV particles in the apical recycling endosome, whereupon the virus is bound and secreted back out into the lumen with the IgA (31). The mechanism of this type of intracellular neutralization is not fully understood; however, it is unlikely to involve TRIM21 as transcytosing IgA is not thought to become cytoplasmically accessible and because pIgR binding to Fcα would be predicted to occlude TRIM21 binding (15) 
Materials and Methods
For full details, see SI Materials and Methods.
Cells, Virus, and Antibodies. HeLa, MEF, and 293F cells were maintained in standard conditions. Human E1, E3-adenovirus 5 vector bearing a GFP transgene (AdV) (32) was purchased from Viraquest. WT human adenovirus 5 (WT AdV) was purchased from ATCC. hIgA was purchased from Athens Research and Technology, and hIgG from Sigma. 9C12 was purified as previously described (11) . To make the 9A antibody, synthetic genes encoding the V H domain, C H 1 domain, and hinge region sequences of 9C12 were combined with C α 2 and C α 3 domains of human IgA1 and expressed in 293F cells from a bicistronic protein expression vector pBUD.CE4.1 (Invitrogen), which also carried the 9C12 light chain (11) . The C α 2 and C α 3 domain boundaries were based on the published IgA Fc crystal structure and lack the C-terminal 18 amino acids normally found in IgA (33) . These residues have previously been shown not to be necessary for FcαRI interaction, which overlaps the TRIM21 binding site. S-IgA was obtained from Sigma (I1010), Athens (16-13-090701), AbD (PHP133), Biorad (0855905), or Invivogen (ctrl-iga).
ELISAs. Cytokine ELISAs were carried out on supernatant harvested 24 h after infection and analyzed following the manufacturer's instructions (Life Technologies). Plates were quantified using a SpectraMAX 340PC (Molecular Devices) at 450 and 650 nm.
Immunofluorescence. Slides were imaged using a Zeiss 63× lens on a Jena LSM 710 microscope (Carl Zeiss MicroImaging).
Virus Neutralization Assays. For GFP-Adv, the %GFP-positive cells was enumerated using flow cytometry as previously described (9) . For replicating virus, cell viability was determined 7 d after infection by MTT assay (Sigma).
Luciferase Reporter Assay. HeLa EV and HeLa shT21 cells were transfected with pGL4.32 NF-κB luciferase reporter construct (Promega). Seven hours after infection, luciferase reagent (Perkin-Elmer) was added, and activity was measured on a BMG Pherastar FS platereader.
Fluorescence Anisotropy. The TRIM21 PRYSPRY domain was expressed, purified, and Alexa Fluor labeled as previously described (8, 10, 13) . IgA was titrated into 50 nM PRYSPRY, and anisotropy experiments were performed as previously described (8) .
Model and Sequence Alignment. The molecular models based on Protein Data Bank (PDB) ID code 2IWG (10, 13) and PDB ID code 1OW0 (19) were superposed in Coot (20) and built using MacPyMOL (Schrodinger). Sequence alignments were performed using DNADynamo (Blue Tractor Software).
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Bidgood et al. 10 .1073/pnas.1410980111 SI Materials and Methods Cells and Virus. HeLa and mouse embryonic fibroblast (MEF) cell lines were grown in DMEM supplemented with 10% (vol/vol) FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin in a 5% (vol/vol) CO 2 atmosphere at 37°C. HeLa cells were depleted of tripartite motif-containing protein 21 (TRIM21) by transfection with siRNA oligonucleotides or stably by transduction with a small-hairpin (sh)RNA-encoding retroviral vector pSIREN-T21 and selection with 2 μg/mL puromycin as previously described (1, 2) . MEF cells were extracted from WT or TRIM21 KO C57/B6 mice (3) as previously described (2) . 293F cells (Invitrogen) were maintained in serum-free Freestyle medium (Invitrogen) in an 8% (vol/vol) CO 2 atmosphere at 37°C using an orbital shaker at 200 × g. Human E1, E3-adenovirus 5 vector bearing a GFP transgene (AdV) (4) was purchased from Viraquest. Viral titer in HeLa and MEF cells was determined as previously described (2) . WT human adenovirus 5 (WT AdV), purchased from ATCC, was grown in HeLa cells, and cell supernatant was frozen 8 d after infection. WT AdV was then purified by double CsCl gradients as previously described (1) . Viral titer was quantified by tissue culture infectious dose (TCID) 50 .
Antibodies and Immunoblotting. Pooled human plasma IgA was obtained from Athens Research and Technology. Pooled human serum IgG (hIgG) was purchased from Sigma. Mouse monoclonal anti-adenovirus hexon IgG antibody, 9C12, was purified from hybridoma supernatant as previously described (2) . To make the 9A antibody, synthetic genes encoding the V H domain, C H 1 domain, and hinge region sequences of 9C12 (L1-V234) were combined with C α 2 and C α 3 domains of human IgA1 (C242-K454; Genscript) (5, 6) . The synthetic gene was cloned into a bicistronic protein expression vector pBUD. CE4.1 (Invitrogen), which already carried the 9C12 light chain (2) . The protein was expressed in 293F cells by transfection with FreeStyle Max (Invitrogen) and purified after 6 d using peptide M-agarose (Invivogen) according to the manufacturer's protocol. Immunoblotting was performed as previously described (1) using mouse monoclonal anti-TRIM21 antibody D12 (Santa Cruz Biotechnology) or rabbit polyclonal anti-β-actin serum (Cell Signaling). The buffer used to dilute all IgA antibodies was 100 mM Tris, pH 8.0, and 100 mM NaCl, and the buffer used to dilute all IgG antibodies was PBS.
Immunofluorescence. HeLa cells were seeded onto coverslips at 2.5 × 10 4 cells per well in 24-well plates and allowed to adhere overnight. AdV (5 × 10 4 IU) was incubated with 75 μg hIgA in 30 μL total for 30 min at room temperature before addition of 220 μL DMEM. Cells were washed with DMEM and then infected with 250 μL of the AdV:hIgA complexes in a DMEM mixture for 30 min at 37°C. Cells were washed, fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and then blocked with 5% BSA. Immunostaining for TRIM21 was performed using a mouse polyclonal antibody raised against the TRIM21ΔPRYSPRY protein, and lysine-48-specific ubiquitin was performed using a rabbit monoclonal (Millipore). Intracellular IgA was detected using FITC-conjugated goat polyclonal (Novus Biologicals), and AdV was detected using 9C12. Labeling was detected using Alexa Fluor-conjugated secondary antibodies (Life Technologies). Coverslips were mounted on medium containing DAPI and imaged using a Zeiss 63× lens on a Jena LSM 710 microscope (Carl Zeiss MicroImaging).
Virus Neutralization Assays. Cells were seeded in six-well plates at 1 × 10 5 cells per well in 1.5 mL of media and allowed to adhere overnight. Where appropriate, cells were depleted of TRIM21 by siRNA as described above or were treated with 1,000 U/well of human IFN-α (Sigma-Aldrich) 16 h before infection. When used, DMSO, the proteasome inhibitors epoxomicin (2 μM; Calbiochem) or MG132 (10 μM; Sigma Aldrich), the valosin-containing protein inhibitor N2,N4-dibenzylquinazoline-2,4-diamine (10 μM; BioVisions), and the autophagy inhibitor Gö6976 (0.5 μM; Millipore) were added to cells by replacing media on cells with media containing the appropriate concentration of inhibitor 4 h before infection. Virus was diluted with buffer to 3 × 10 4 IU in 10 μL and mixed with either 10 μL of 9C12 or 9A or with 15 μL hIgA at the stated concentrations for 1 h to allow binding and then were added to cells. After incubation for 16 h at 37°C, the percentage of GFPpositive cells was enumerated using flow cytometry as previously described (1) . Multiplicity of infection (MOI) was calculated using the following equation: MOI = −lnf½100 − ð% GFP positiveÞ= 100g Remaining infectivity (I/I 0 ) was calculated by dividing the MOI after antibody treatment by that of buffer control. x axis values are expressed in milligrams per milliliter or micrograms per milliliter of the input antibody before being mixed with AdV. Fold neutralization is equal to I 0 /I.
Restricting Titer Experiment. Cells were plated at 5 × 10 3 per well in 96-well plates into DMEM supplemented with 2% FCS. Serial dilutions of 80 μg/mL 9A or 9C12 or 2 mg/mL hIgA were incubated with 20× TCID 50 units of WT adenovirus (ATCC) for 1 h before addition to cells. Seven days after infection, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma) assay was performed, first incubating cells in 5 μg/mL MTT reagent for 4 h and then permeabilizing cells by DMSO and measuring the absorbance with a SpectraMAX 340PC (Molecular Devices) at 540 nm.
Luciferase Reporter Assay. HeLa EV and HeLa shT21 cells (1.5 × 10 6 ) were plated on a 10-cm dish and allowed to adhere overnight. The cells were transfected with pGL4.32 NF-κB luciferase reporter construct (Promega) using Fugene6 (Promega) 48 h before infection. Cells were replated into 96-well plates at 5 × 10 3 cells per well 24 h before infection. Virus and hIgA or hIgG at 10 mg/mL were incubated 1:7 for 1 h before addition to cells. AdV was added to the cells at 7.5 × 10 5 IU/well. For a positive control, cells were challenged with recombinant TNF-α at 10 pg/mL. Cells were incubated for 7 h at 37°C before addition of 100 μL Steadylite Plus luciferase reagent (PerkinElmer) and reading on a BMG Pherastar FS platereader. Data are represented as fold increase over the mean of triplicate PBStreated control cells.
Fluorescence Anisotropy. The TRIM21 PRYSPRY domain was expressed and purified as previously described (7, 8) . The protein was labeled with Alexa Fluor 488 5-SDP ester (Invitrogen) and dialyzed into 50 mM Tris (pH 8) with 200 mM NaCl. Anisotropy experiments were performed using a Cary Eclipse fluorescence spectrophotometer (Varian) with excitation at 488 nm and emission at 530 nm, using 10-nm slit widths and a photomultiplier voltage of 600. hIgA was titrated into 50 nM PRYSPRY, and the polarized fluorescence was averaged over 5 s. The dissociation constant (K D ) was determined by fitting the change in anisotropy to the quadratic expression where F is the observed fluorescence, F TR is the molar TRIM21 fluorescence, f′ is the molar change in fluorescence, TR 0 is the total TRIM21 concentration, I 0 is the total antibody concentration, and K D is the dissociation constant. (5) . The heavy chains in the two complexes were superposed using the secondary-structure matching (SSM) algorithm implemented in Coot (9) . The models were built and analyzed using MacPyMOL (Schrodinger). Sequence alignments were performed using DNADynamo (Blue Tractor Software). 
